军事知识服务平台
基于外周血中期因子、解整合素样金属蛋白酶10及血管生成素样蛋白3水平联合临床生化指标构建糖尿病视网膜病变分层模型
Construction of a risk stratification model for diabetic retinopathy based on peripheral blood midkine, a disintegrin and metalloproteinase domain-containing protein 10, angiopoietin-like protein 3 levels, and conventional biochemical parameters
摘要 目的:初步探讨血清中期因子(Midkine)、解整合素样金属蛋白酶10(ADAM10)及血管生成素样蛋白3(ANGPTL3)水平与糖尿病视网膜病变(DR)发生及进展的关系,并基于上述血清标志物构建DR风险分层模型。方法:横断面研究。2024年6月至2025年6月于泰州市中医院内分泌科和(或)眼科住院治疗的2型糖尿病(T2DM)患者152例(300只眼)纳入研究。根据DR严重程度,将患者分为无DR(NDR)组、非增生型DR(NPDR)组和增生型DR(PDR)组,各组分别为50例(100只眼)、61例(120只眼)和41例(80只眼)。系统收集患者人口学特征及实验室检测数据,包括血糖、血脂及血清Midkine、ADAM10、ANGPTL3水平。采用广义线性混合效应模型(GLMM,Logit链接函数)筛选DR发生及进展的独立危险因素,计算比值比及其95%可信区间;基于GLMM回归系数( β系数)赋分法构建3个风险分层模型:模型1仅纳入传统临床指标[包括T2DM病程、空腹血糖(FBG)、糖化血红蛋白(HbA1c)、低密度脂蛋白胆固醇(LDL-C)及高密度脂蛋白胆固醇(HDL-C)];模型2仅纳入血清标志物(Midkine、ADAM10、ANGPTL3);模型3为全模型(传统指标联合血清标志物)。采用受试者工作特征曲线及曲线下面积(AUC)评估各模型的预测效能,并通过10折交叉验证评估模型的预测准确率。 结果:与NDR组相比,NPDR组及PDR组患者的T2DM病程( F=89.21)、FBG( F=19.87)、HbA1c( F=74.35)、LDL-C( F=16.92)、Midkine( F=162.18)、ADAM10( F=69.85)及ANGPTL3( F=4.47)水平均显著升高,而HDL-C水平显著降低( F=18.95),差异均有统计学意义( P<0.05)。GLMM分析显示,T2DM病程、FBG、HbA1c、LDL-C、Midkine、ADAM10及ANGPTL3水平升高均可显著增加DR发生及进展风险( β=0.285、0.256、0.658、0.486、1.135、0.003、0.016, P<0.05),而HDL-C水平升高则降低该风险( β=?0.732, P<0.05)。模型1、模型2及模型3预测DR发生及进展的AUC分别为0.759、0.847及0.927;10折交叉验证准确率分别为72.10%、80.23%及88.20%。模型3的AUC和交叉验证准确率均显著高于模型1及模型2,差异均有统计学意义( P<0.05)。模型3评分范围为?12.3~18.7分,按三分位数划分为低风险(≤2.1分)、中风险(2.2~8.5分)和高风险(≥8.6分)三个等级,分别对应NDR、轻度至中度NPDR及重度NPDR至PDR。 结论:血清Midkine、ADAM10及ANGPTL3水平与DR发生及进展呈显著正相关;传统临床指标联合上述血清标志物的全模型对DR发生及进展的预测效能优于单一传统指标模型或单一血清标志物模型。
Abstract:
Objective:To explore the relationship between the levels of serum midkine (Midkine), a disintegrin and metalloproteinase domain-containing protein 10 (ADAM10), and angiopoietin-like protein 3 (ANGPTL3) and the occurrence and progression of diabetic retinopathy (DR), and to construct a DR risk stratification model incorporating the aforementioned serum markers.Methods:A cross-sectional study. A total of 152 patients with type 2 diabetes (T2DM) (including 300 eyes) who were hospitalized in Department of Ophthalmology and/or Endocrinology of Taizhou Traditional Chinese Medicine Hospital from June 2024 to June 2025 were included in the study. According to the severity of DR, the patients were divided into the no DR (NDR) group, the non-proliferative DR (NPDR) group and the proliferative DR (PDR) group. Each group consisted of 50 cases (100 eyes), 61 cases (120 eyes) and 41 cases (80 eyes), respectively. The demographic characteristics and laboratory test data of patients, including blood glucose, blood lipids, and serum levels of Midkine, ADAM10, and ANGPTL3 were systematically collected. The generalized linear mixed-effects model (GLMM, Logit link function) was used to screen the independent risk factors for the occurrence and progression of DR, and calculate the odds ratio and its 95% confidence interval. Three risk-stratification models were developed via scoring based on GLMM regression coefficients ( β-coefficients): Model 1 included only conventional clinical indicators [T2DM duration, fasting blood glucose (FBG), glycated hemoglobin (HbA1c), low-density lipoprotein-cholesterol (LDL-C), high-density lipoprotein-cholesterol (HDL-C)]. Model 2 incorporated solely serum biomarkers (Midkine, ADAM10, ANGPTL3); Model 3 was the full combined model integrating both conventional indicators and serum biomarkers. Receiver-operating characteristic curves and the area under the curve (AUC) were applied to evaluate predictive performance of each model, and 10-fold cross-validation was performed to assess model prediction accuracy. Results:Compared with the NDR group, the NPDR and PDR groups exhibited elevated levels of T2DM duration ( F=89.21), FBG ( F=19.87), HbA1c ( F=74.35), LDL-C ( F=16.92), Midkine ( F=162.18), ADAM10 ( F=69.85), and ANGPTL3 ( F=4.47), accompanied by decreased HDL-C level ( F=18.95). All differences were statistically significant ( P<0.05). GLMM analysis demonstrated that increased levels of T2DM duration, FBG, HbA1c, LDL-C, Midkine, ADAM10, and ANGPTL3 significantly raised the risk of DR onset and progression ( β = 0.285, 0.256, 0.658, 0.486, 1.135, 0.003, 0.016; P<0.05), whereas elevated HDL-C level reduced such risk ( β=?0.732, P<0.05). GLMM analysis revealed that elevated levels of T2DM duration, FBG, HbA1c, LDL-C, Midkine, ADAM10, and ANGPTL3 significantly increased the risk of DR onset and progression ( β=0.285, 0.256, 0.658, 0.486, 1.135, 0.003, 0.016; P<0.05), whereas increased HDL-C level reduced this risk ( β = ?0.732, P<0.05). The AUCs of Model 1, 2 and 3 for predicting DR onset and progression were 0.759, 0.847 and 0.927, with 10-fold cross-validation accuracies of 72.10%, 80.23% and 88.20%, respectively. Model 3 had statistically superior AUC and cross-validation accuracy versus Model 1 and Model 2 ( P<0.05). Model 3 produced risk scores ranging from ?12.3 to 18.7. Eyes were stratified into low-risk (≤2.1), medium-risk (2.2-8.5), and high-risk (≥8.6) subgroups according to score tertiles, which correspond to NDR, mild-to-moderate NPDR, and severe NPDR-PDR respectively. Conclusions:Serum levels of Midkine, ADAM10 and ANGPTL3 are significantly positively correlated with the onset and progression of DR. The full-combined model exhibits better predictive performance for DR onset than single-model approaches using either conventional indicators or serum biomarkers alone.